Advanced topics in evidence-based urologic oncology

Surrogate endpoints

Luke T. Lavallée, Victor Manuel Montori, Stephen E. Canfield, Rodney H. Breau

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Clinical trials often report surrogate endpoint data. A surrogate endpoint is a biological marker or clinical sign that can be substituted for a patient-important outcome. Using surrogate endpoints correctly may facilitate and expedite clinical trials and may improve medical decisions. However, rigorous criteria must be met for an endpoint to be considered a valid surrogate. The purpose of this article is to review the topic of surrogate endpoints in the context of a urologic encounter.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume29
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Biomarkers
Clinical Trials

Keywords

  • Biological Markers
  • Data Interpretation
  • Evidence-based medicine
  • Surrogate endpoints

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Advanced topics in evidence-based urologic oncology : Surrogate endpoints. / Lavallée, Luke T.; Montori, Victor Manuel; Canfield, Stephen E.; Breau, Rodney H.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 29, No. 4, 07.2011, p. 447-453.

Research output: Contribution to journalArticle

Lavallée, Luke T. ; Montori, Victor Manuel ; Canfield, Stephen E. ; Breau, Rodney H. / Advanced topics in evidence-based urologic oncology : Surrogate endpoints. In: Urologic Oncology: Seminars and Original Investigations. 2011 ; Vol. 29, No. 4. pp. 447-453.
@article{26cb5af365cd43599175b0d159b47d7a,
title = "Advanced topics in evidence-based urologic oncology: Surrogate endpoints",
abstract = "Clinical trials often report surrogate endpoint data. A surrogate endpoint is a biological marker or clinical sign that can be substituted for a patient-important outcome. Using surrogate endpoints correctly may facilitate and expedite clinical trials and may improve medical decisions. However, rigorous criteria must be met for an endpoint to be considered a valid surrogate. The purpose of this article is to review the topic of surrogate endpoints in the context of a urologic encounter.",
keywords = "Biological Markers, Data Interpretation, Evidence-based medicine, Surrogate endpoints",
author = "Lavall{\'e}e, {Luke T.} and Montori, {Victor Manuel} and Canfield, {Stephen E.} and Breau, {Rodney H.}",
year = "2011",
month = "7",
doi = "10.1016/j.urolonc.2010.06.010",
language = "English (US)",
volume = "29",
pages = "447--453",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Advanced topics in evidence-based urologic oncology

T2 - Surrogate endpoints

AU - Lavallée, Luke T.

AU - Montori, Victor Manuel

AU - Canfield, Stephen E.

AU - Breau, Rodney H.

PY - 2011/7

Y1 - 2011/7

N2 - Clinical trials often report surrogate endpoint data. A surrogate endpoint is a biological marker or clinical sign that can be substituted for a patient-important outcome. Using surrogate endpoints correctly may facilitate and expedite clinical trials and may improve medical decisions. However, rigorous criteria must be met for an endpoint to be considered a valid surrogate. The purpose of this article is to review the topic of surrogate endpoints in the context of a urologic encounter.

AB - Clinical trials often report surrogate endpoint data. A surrogate endpoint is a biological marker or clinical sign that can be substituted for a patient-important outcome. Using surrogate endpoints correctly may facilitate and expedite clinical trials and may improve medical decisions. However, rigorous criteria must be met for an endpoint to be considered a valid surrogate. The purpose of this article is to review the topic of surrogate endpoints in the context of a urologic encounter.

KW - Biological Markers

KW - Data Interpretation

KW - Evidence-based medicine

KW - Surrogate endpoints

UR - http://www.scopus.com/inward/record.url?scp=79959860951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959860951&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2010.06.010

DO - 10.1016/j.urolonc.2010.06.010

M3 - Article

VL - 29

SP - 447

EP - 453

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -